Producer
Noramco Inc.
US specialty pharmaceutical API manufacturer (HQ Wilmington, Delaware; formerly a Johnson & Johnson subsidiary, spun off to SK Capital Partners in 2016); the largest US-based manufacturer of controlled substance APIs including buprenorphine, fentanyl, methadone, hydrocodone, and oxycodone. Noramco holds a DEA Schedule II/III bulk manufacturer registration and manufactures buprenorphine API at its Athens, Georgia facility under annual DEA-approved manufacturing quotas. Noramco is the primary US-sourced buprenorphine API supplier to Indivior (Suboxone sublingual film), Reckitt Benckiser legacy operations, and dozens of generic buprenorphine/naloxone tablet and film manufacturers. During the opioid epidemic response, Noramco's Athens facility scaled production significantly as DEA quotas were repeatedly increased to meet surging demand for medication-assisted treatment (MAT). Noramco also manufactures thebaine-derived synthetic opioids, making it a vertically positioned US controlled substance API platform. Following the Suboxone film patent cliff (2023-2024), Noramco's buprenorphine API demand increased further as dozens of generic manufacturers entered the market.
3
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
3 inputs Noramco Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Noramco Inc. makes, pick one to see the full supply chain.
Where they make it
2 facilities
Noramco Inc. — Athens, Georgia API Plant →
USGeorgia · manufacturing
Noramco's Athens, Georgia facility is the primary US manufacturing site for buprenorphine API and other Schedule I/II controlled substance APIs (fentanyl, methadone, hydrocodone). DEA bulk manufacturer registration. Annual buprenorphine production under DEA-approved quota that expanded significantly during opioid epidemic response — DEA increased buprenorphine quota from ~7,000 kg in 2012 to ~27,000 kg by 2020. The Athens facility is the most consequential single site for US OUD treatment supply. Source: https://www.deadiversion.usdoj.gov/fed_regs/quotas/index.html
Noramco Inc. — Wilmington, Delaware HQ/R&D →
USDelaware · hq
Noramco corporate headquarters and R&D in Wilmington, Delaware. DEA Schedule I/II registration site for API development and analytical testing. Formerly part of Johnson & Johnson API division before SK Capital Partners acquisition in 2016. Source: https://www.noramco.com/about/
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Opioid Pain Management APIs
45%Addiction Treatment APIs
35%Specialty Controlled APIs
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Noramco manufactures both fentanyl API (for legitimate pharmaceutical pain management — fentanyl patches used by cancer and chronic pain patients) AND buprenorphine API (the frontline medication-assisted treatment for opioid use disorder, sold as Suboxone and generic formulations). The same Noramco manufacturing facility in Wilmington, Delaware produces the API used in products treating opioid addiction AND the API present (in very different formulations and delivery systems) in the pharmaceutical category that contributed to the addiction crisis. From a single US API manufacturer, the pharmaceutical pain management supply chain and the opioid addiction treatment supply chain are literally manufactured side by side — two supply chains that public health systems and advocacy groups treat as separate, but that pharmaceutical API buyers know converge at Noramco.
Noramco Inc ↗Origin2023
Noramco began as a Johnson & Johnson subsidiary — the consumer healthcare and pharmaceutical company known for Tylenol, Band-Aid, and baby products. J&J built a controlled substance API manufacturing capability at Noramco to supply its own pharmaceutical brands. SK Capital Partners, a specialty private equity firm focused on chemicals and materials, acquired Noramco from J&J in 2016 for an undisclosed price. The spinoff created the largest independent US-based controlled substance API manufacturer, separated from the consumer brand associations of its former parent. J&J itself later paid billions in opioid settlement payments related to its role in the opioid crisis — Noramco had been part of that supply chain.
Noramco Inc ↗Concentration2018
Noramco Inc. (Athens, Georgia) manufactures the majority of US-consumed buprenorphine API and is also one of the primary US manufacturers of fentanyl API for legitimate pharmaceutical use (fentanyl patches, lozenges, and injectables). The same company — the same Athens, Georgia facility — that produces the medication-assisted treatment (buprenorphine) that saves lives from opioid overdose also produces the opioid (fentanyl) that is the leading cause of overdose deaths when diverted from its pharmaceutical supply chain or manufactured illicitly. Noramco's DEA-authorized fentanyl quota covers pharmaceutical-grade fentanyl for legitimate medical products like Duragesic patches and Actiq lozenges; illicitly manufactured fentanyl that kills tens of thousands of Americans annually is synthesized in China and Mexico from different chemical precursors. Nevertheless, the same US company holds DEA registrations for both the treatment and (the pharmaceutical precursor chemical pathway for) the cause of the opioid epidemic's most lethal phase. This is not a criticism of Noramco — both products serve legitimate medical purposes — but it illustrates the extraordinary regulatory complexity of operating a controlled substance API business in the US.
Federal Register / Drug Enforcement Administration (DEA) ↗